BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, Zheng T. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol 2021;14:1756284821989177. [PMID: 34262609 DOI: 10.1177/1756284821989177] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
Number Citing Articles
1 Shi X, Wang C, Meng F, Ma S, Xu G, Liu T, Guo X, Li H, Qi X. Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study. Postgrad Med 2022. [PMID: 35860966 DOI: 10.1080/00325481.2022.2105094] [Reference Citation Analysis]
2 Graham DY. Comments regarding use of rifabutin for Helicobacter pylori eradication. Therap Adv Gastroenterol 2021;14:17562848211044064. [PMID: 34646357 DOI: 10.1177/17562848211044064] [Reference Citation Analysis]
3 Zhao H, Yan P, Zhang N, Feng L, Chu X, Cui G, Qin Y, Yang C, Wang S, Yang K. The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis. Helicobacter 2021;26:e12852. [PMID: 34510644 DOI: 10.1111/hel.12852] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Yuan Z, Xiao S, Li S, Suo B, Wang Y, Meng L, Liu Z, Yin Z, Xue Y, Zhou L. The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter 2021;26:e12848. [PMID: 34448282 DOI: 10.1111/hel.12848] [Cited by in F6Publishing: 10] [Reference Citation Analysis]